{
    "PF-05212384 (gedatolisib); PF-00299804": "null",
    "B2151002": "null",
    "Final Protocol Amendment 5, 11 November 2016": "null",
    "TABLE OF CONTENTS": "null",
    "LIST OF TABLES": "34",
    "LIST OF FIGURES": "34",
    "APPENDICES": "35",
    "1. INTRODUCTION": "36",
    "1.1. Indication \u2013Original Protocol through Amendment 4": "36",
    "1.2. Indication \u2013Amendment 5": "36",
    "1.3. Background": "36",
    "1.3.1. PI3K/mTOR": "36",
    "1.3.2. PF-05212384": "38",
    "1.3.2.1. Preclinical Data for PF-05212384": "38",
    "1.3.3. PF-05212384 Clinical Experience": "39",
    "1.3.3.1. Phase 1 Study of PF-05212384 Single Agent in Patients": "null",
    "with Advanced Solid Tumors (B2151001)": "39",
    "1.3.3.2.Phase 1 Study of PF-05212384 in Combination with": "null",
    "Irinotecan in Patients with Advanced Solid Tumors": "null",
    "(B1271002)": "41",
    "1.3.3.3. Phase 2 Study of PF-05212384 Single Agent in Patients": "null",
    "with Advanced Endometrial Cancer (B1271004)": "41",
    "1.3.4. Docetaxel": "42",
    "1.3.5. Cisplatin": "42",
    "1.3.5.1. PF-05212384 Plus Cisplatin in Patients with TNBC": "43",
    "1.3.6. Dacomitinib (PF-00299804)": "43",
    "1.3.7. Study Rationale": "46",
    "1.3.7.1. Rationale for Combinations": "47",
    "1.3.7.2. Rationale for PF-05212384 Doses": "49",
    "1.3.7.3. Rationale for Docetaxel, Cisplatin and Dacomitinib": "null",
    "Starting Doses": "49",
    "1.4. Overall Risk Benefit Assessment": "49",
    "2. STUDY OBJECTIVES AND ENDPOINTS": "50",
    "2.1. Objectives \u2013Original Protocol through Amendment 4": "50",
    "2.2. Endpoints \u2013 Original Protocol through Amendment 4": "50",
    "2.3. Objectives -Safety and Efficacy Expansion in Patients with TNBC": "51",
    "PFIZER CONFIDENTIAL": "null",
    "Page 28": "null",
    ")TMG(": "null",
    "54:90": "null",
    "1202-naJ-60": "null",
    ":nO": "null",
    "devorppA\\devorppA\\e0b52f591e771090": "null",
    "2.4. Endpoints -Safety and Efficacy Expansion in Patients with TNBC": "51",
    "3. STUDY DESIGN": "52",
    "3.1. Dose Levels to Be Tested": "54",
    "3.1.1. Criteria for Dose Assignment": "56",
    "3.1.1.1. Criteria for Dose Assignments for Arms A and B": "56",
    "3.1.1.2. Criteria for Dose Assignment for Arm C": "58",
    "3.2. DLT Definition (All Arms)": "59",
    "3.3. MTD Definition": "60",
    "3.4. Safety and Efficacy Expansion in Patients with TNBC": "60",
    "3.4.1. Dose Rationale": "61",
    "4. PATIENT SELECTION": "61",
    "4.1. Inclusion Criteria \u2013 Original Protocol through Amendment 4": "62",
    "4.2. Exclusion Criteria\u2013Original Protocol through Amendment 4": "64",
    "4.3. Inclusion Criteria \u2013 Safety and Efficacy Expansion in patients with TNBC": "66",
    "4.4. Exclusion Criteria \u2013Safety and Efficacy Expansion in patients with TNBC": "68",
    "4.5. Life Style Guidelines": "70",
    "4.6. Sponsor Qualified Medical Personnel": "71",
    "5. STUDY TREATMENTS": "71",
    "5.1. Allocation to Treatment": "71",
    "5.1.1. Dose Escalation Portion of B2151002": "71",
    "5.1.2. Safety and Efficacy Expansion in Patients with TNBC": "72",
    "5.2. Drug Supplies": "72",
    "5.2.1. Formulation and Packaging": "73",
    "5.2.1.1. PF-05212384": "73",
    "5.2.1.2. Docetaxel": "73",
    "5.2.1.3. Cisplatin": "73",
    "5.2.1.4. Dacomitinib": "73",
    "5.2.2. Preparation and Dispensing": "73",
    "5.2.2.1. PF-05212384": "73",
    "5.2.2.2. Docetaxel": "74",
    "5.2.2.3. Cisplatin": "74",
    "5.2.2.4. Dacomitinib": "74",
    "Page 29": "null",
    "5.2.3. Administration": "74",
    "5.2.3.1. PF-05212384": "74",
    "5.2.3.2. Docetaxel": "75",
    "5.2.3.3. Cisplatin": "75",
    "5.2.3.4. Dacomitinib": "76",
    "5.2.4. Medication Errors": "76",
    "5.2.5. Recommended Dose Modifications": "77",
    "5.2.6. Dose Interruptions/Delay": "77",
    "5.2.7. Dose Reductions": "78",
    "5.2.7.1. PF-05212384": "79",
    "5.2.7.2. Docetaxel": "81",
    "5.2.7.3. Cisplatin": "82",
    "5.2.7.4. Dacomitinib": "83",
    "5.2.8. Compliance": "84",
    "5.2.8.1. PF-05212384, Docetaxel, and Cisplatin": "84",
    "5.2.8.2. Dacomitinib": "84",
    "5.3. Drug Storage and Drug Accountability": "85",
    "5.3.1. PF-05212384": "85",
    "5.3.2. Docetaxel and Cisplatin": "86",
    "5.3.3. Dacomitinib": "86",
    "5.4. Concomitant Medication(s)": "86",
    "5.4.1. Drugs Interacting with CYP3A4": "86",
    "5.4.2. CYP2D6 Substrates (Arm C only)": "87",
    "5.4.3. P-glycoprotein Substrates (Arm C only)": "88",
    "5.4.4. Strong Amines (Arm C only)": "88",
    "5.4.5. Other Anti-tumor/Anti-cancer or Experimental Drugs": "88",
    "5.4.6. Supportive Care": "88",
    "5.4.7. Hematopoietic Growth Factors": "88",
    "5.4.8. Corticosteroids": "89",
    "5.4.9. Surgery": "89",
    "5.4.10. Oral Mucositis \u2013Prophylaxis and Management": "89",
    "6. STUDY PROCEDURES": "90",
    "Page 30": "null",
    "6.1. Screening": "90",
    "6.2. Study Period": "91",
    "6.3. Follow-up Visit": "91",
    "6.4. Patient Withdrawal": "91",
    "7. ASSESSMENTS": "93",
    "7.1. Safety Assessments": "93",
    "7.1.1. Pregnancy Testing": "93",
    "7.1.2. Adverse Events": "93",
    "7.1.3. Laboratory Safety Assessments": "94",
    "7.1.4. Vital Signs and Physical Examination": "94",
    "7.1.5. (12-Lead) ECG": "94",
    "7.1.6. Left Ventricular Ejection Fraction Measurements (Arm C only)": "95",
    "7.2. Pharmacokinetics Assessments": "96",
    "7.2.1. Pharmacokinetic Assessments in the Safety and Efficacy Expansion": "null",
    "in TNBC": "96",
    "7.3. Pharmacodynamic Assessments": "97",
    "7.3.1. Tumor Biopsy": "98",
    "7.3.2. Whole Blood/Plasma Biospecimens": "99",
    "7.3.3. Effect of PI3K Inhibition on Glucose Metabolism": "99",
    "7.4. Tumor Response Assessments": "99",
    "(cid:38)(cid:38)(cid:44) 100": "null",
    "(cid:38)(cid:38)(cid:44) 101": "null",
    "7.6. Patient Reported Outcomes in the Safety and Efficacy Expansion in TNBC": "101",
    "7.6.1. EORTC QLQ-C30 and EORTC QLQ-BR23": "102",
    "8. ADVERSE EVENT REPORTING": "102",
    "8.1. Adverse Events": "102",
    "8.2. Reporting Period": "103",
    "8.3. Definition of an Adverse Event": "103",
    "8.4. Abnormal Test Findings": "104",
    "8.5. Serious Adverse Events": "104",
    "8.5.1. Protocol-Specified Serious Adverse Events": "105",
    "Page 31": "null",
    "8.5.2. Potential Cases of Drug-Induced Liver Injury": "105",
    "8.6. Hospitalization": "107",
    "8.7. Severity Assessment": "108",
    "8.8. Causality Assessment": "108",
    "8.9. Exposure During Pregnancy": "109",
    "8.10. Occupational Exposure": "110",
    "8.11. Withdrawal Due to Adverse Events (See also Section Patient Withdrawal)": "110",
    "8.12. Eliciting Adverse Event Information": "110",
    "8.13. Reporting Requirements": "110",
    "8.13.1. Serious Adverse Event Reporting Requirements": "110",
    "8.13.2. Non-Serious Adverse Event Reporting Requirements": "111",
    "8.13.3. Sponsor\u2019s Reporting Requirements to Regulatory Authorities": "111",
    "9. DATA ANALYSIS/STATISTICAL METHODS": "111",
    "9.1. Analysis Sets": "111",
    "9.2. Statistical Methods and Properties": "113",
    "9.2.1. Statistical Methods for Arms A and B": "113",
    "9.2.2. Statistical Method for Arm C": "114",
    "9.2.3. Statistical Method for the Safety and Efficacy Expansion Arm 1 and": "null",
    "2": "114",
    "9.3. Sample Size Determination": "114",
    "9.4. Efficacy Analysis": "115",
    "9.4.1. Efficacy Analysis for the Dose Escalation": "115",
    "9.4.2. Efficacy Analysis for the Safety and Efficacy Expansion in TNBC": "116",
    "9.5. Analysis of Other Endpoints": "116",
    "9.5.1. Analysis of Single- and Multiple-Dose Pharmacokinetics": "116",
    "9.5.1.1. Metabolite Profiling": "117",
    "9.5.2. Statistical Analysis of Biomarkers": "117",
    "9.6. Safety Analysis": "117",
    "9.6.1. Analysis of Primary Endpoint": "117",
    "9.6.2. Analysis of Secondary Safety Endpoints": "117",
    "9.6.2.1. Adverse Events": "117",
    "9.6.2.2. Laboratory Tests Abnormalities": "118",
    "Page 32": "null",
    "9.6.2.3. Electrocardiogram Assessments": "118",
    "9.7. Patient Reported Outcomes": "118",
    "9.8. Data Safety Monitoring Committee": "119",
    "10. QUALITY CONTROL AND QUALITY ASSURANCE": "119",
    "11. DATA HANDLING AND RECORD KEEPING": "119",
    "11.1. Case Report Forms/Electronic Data Records": "119",
    "11.2. Record Retention": "120",
    "12. ETHICS": "120",
    "12.1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC)": "120",
    "12.2. Ethical Conduct of the Study": "121",
    "12.3. Patient Information and Consent": "121",
    "12.4. Patient Recruitment": "121",
    "12.5. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH": "null",
    "GCP": "122",
    "13. DEFINITION OF END OF TRIAL": "122",
    "13.1. End of Trial in a Member State": "122",
    "13.2. End of Trial in all other Participating Countries": "122",
    "14. SPONSOR DISCONTINUATION CRITERIA": "122",
    "15. PUBLICATION OF STUDY RESULTS": "122",
    "15.1. Communication of Results by Pfizer": "122",
    "15.2. Publications by Investigators": "123",
    "16. REFERENCES": "125",
    "Page 33": "null"
}